Advertisement

Drugs

, Volume 44, Issue 4, pp 625–655 | Cite as

Nicorandil

A Review of its Pharmacology and Therapeutic Efficacy in Angina Pectoris
  • James E. Frampton
  • Micaela M. Buckley
  • Andrew Fitton
Drug Evaluation

Summary

Synopsis

Nicorandil belongs to the class of compounds known as potassium channel activators which are characterised by their arterial vasodilator properties. In addition, nicorandil has venodilating properties which are attributable to a nitrate group in its chemical structure. Therefore, by combining these two vasodilator mechanisms, nicorandil represents a novel type of compound for use in the treatment of angina pectoris. Furthermore, increasing experimental evidence suggests that potassium channel activation may also exert a direct cytoprotective effect by augmenting normal physiological processes which protect the heart against ischaemic events.

Comparative studies of up to 3 months’ duration suggest that nicorandil is equivalent in efficacy to isosorbide dinitrate, propranolol, atenolol, nifedipine or diltiazem in the treatment of stable angina. Preliminary evidence suggests that an improvement of anginal and ischaemic symptoms is maintained for up to 1 year. Whilst the efficacy of nicorandil in other types of angina has not been extensively studied, preliminary results indicate that intravenous nicorandil is as effective as isosorbide dinitrate in the treatment of unstable angina and is also effective in patients with variant angina. In addition, the limited data available indicate that nicorandil may be effective in patients with unstable and variant angina who are refractory to therapy with conventional antianginal agents, a potentially important area for further study.

Headache, mostly of mild to moderate intensity was the most commonly reported adverse event, occurring in one-third of patients receiving the recommended therapeutic regimen of nicorandil 10 to 20mg twice daily. In comparative trials involving a total of 84 patients who received nicorandil, the incidence of headache was similar to that produced by isosorbide mononitrate and isosorbide dinitrate. Headache was most frequent on initiating therapy but declined with continued treatment. To date, approximately 5% of patients participating in European trials have withdrawn due to headache, although this rate may be reduced by using a lower starting dose of nicorandil (5mg twice daily).

In summary, clinical experience thus far indicates that nicorandil, with its novel combination of two distinct vasodilator mechanisms, offers an effective alternative to established vasodilator therapy with conventional nitrates and calcium antagonists in the long term treatment of stable angina pectoris. Further studies are warranted to establish whether the unique pharmacodynamic profile of nicorandil is advantageous for the treatment of other types of angina and/or the ischaemic myocardium.

Pharmacodynamic Properties

In patients with cardiovascular disease, the haemodynamic effects of nicorandil which are attributable to its nitrate-like properties include dilation of large coronary arteries (by 10 to 20%) and a spasmolytic action. In addition, as a result of potassium channel activation, intravenous administration of nicorandil (2mg; 0.1 or 0.2 mg/kg) decreased coronary vascular resistance (by 24 to 53%), resulting in an increase in coronary blood flow (of 26 to 93%) in resting subjects. Orally administered nicorandil 15 to 40mg produced a similar but nonsignificant decrease in coronary vascular resistance (by 10 to 32%) and increase in coronary sinus blood flow (⩽32%), although significant effects were measured during exercise in patients with evidence of old myocardial infarction.

At rest, administration of nicorandil intravenously (2 to 8 mg; 0.1 or 0.2 mg/kg) or as a single oral dose (5 to 80mg) decreased systemic vascular resistance (by 5 to 36%) and mean arterial pressure (by 5 to 24%), as well as indicators of venous return such as pulmonary capillary wedge pressure (by 14 to 45%) and left ventricular end-diastolic pressure (by 10 to 143%). Systemic vasodilation was occasionally associated with a transient increase in resting heart rate of up to 18%, although this was not observed in patients with congestive heart failure. Oral nicorandil 15 to 60mg did not consistently affect the systolic blood pressure response to exercise, although a decrease in preload is still evident (33%) and a transient increase in exercise heart rate may be apparent 30 minutes post dose (20 to 30mg).

The haemodynamic effects of nicorandil reach a peak within 1 to 2 minutes of intravenous administration or 30 to 60 minutes after a single oral dose (20 to 40 mg) and persist for up to 8 hours (40 to 60mg).

Several placebo-controlled studies in patients with stable effort angina have indicated that 2 hours after a single oral dose of nicorandil 5 to 60mg there is a significant improvement in anginal symptoms, including an increase in total exercise duration (by 12 to 36%), time to onset of angina (by 20 to 78%) and time to ST segment depression (by 25 to 94%); significant changes in these parameters have been reported 6 hours after a single dose of nicorandil (20 or 60mg) and for up to 12 hours following repeated twice daily administration (10 to 20mg).

In both animal and clinical studies, nicorandil has demonstrated a more prominent effect on systemic vascular resistance (afterload) and coronary blood flow than conventional nitrates. Furthermore, in contrast to nitroglycerin (glyceryl trinitrate), continuous intravenous infusion of nicorandil does not appear to be associated with the development of haemodynamic tolerance over a period of 24 hours, an effect also attributable to its nitrate-independent vasodilator activity as a potassium channel activator. Patients do not appear to develop a significant degree of tolerance to the antianginal effect of nicorandil 10 to 40mg twice daily during long term therapy (⩽ 1 year), although the issue of whether cross-tolerance can develop between nicorandil and conventional nitrates has yet to be resolved.

Thus, nicorandil may improve the balance between myocardial oxygen supply and demand through a combination of coronary vasodilation as well as a balanced decrease in systemic pre-and afterload. In addition, the direct effect of potassium channel activation on cardiac myocytes may account for the cardioprotective effect of nicorandil in animal models of myocardial infarction and ischaemia-reperfusion injury, as well as an anti-ischaemic effect in patients subjected to brief coronary artery occlusion during percutaneous transluminal coronary angioplasty.

Pharmacokinetic Properties

Although the standard pharmacokinetic parameters of nicorandil have been measured in healthy volunteers, there are limited data in patients with cardiovascular disease. A single oral dose of nicorandil 5 to 20mg is rapidly absorbed, reaching peak plasma concentrations in 0.5 to 1 hours, corresponding with the peak systemic haemodynamic effect. Food significantly decreases the rate, but not the extent, of absorption. After a single oral dose (20mg) or intravenous injection (5mg) of nicorandil, the apparent distribution volume is 1 to 1.4 L/kg. In healthy volunteers, oral bio-availability of nicorandil following a 5mg oral dose was generally greater than 75%, suggesting that nicorandil is not subject to extensive ‘first-pass’ hepatic metabolism.

Nicorandil is rapidly eliminated from the plasma with a half-life of about 50 minutes and the plasma concentrations are reduced to 4% of peak values after 8 hours, although very low plasma concentrations are maintained for up to 24 hours due to a further disposition process, possibly involving release of the drug from the endothelium wall of blood vessels.

The main route of elimination from the plasma appears to be denitration by the liver to the pharmacologically inactive alcohol metabolite A -(2-hydroxyethyl)-nicotinamide, followed by urinary excretion. In addition, N-(2-hydroxyethyl)-nicotinamide may be further degraded into nicotinic acid and related metabolites, some of which may become incorporated into cellular pools of these naturally occurring endogenous nucleotides. This latter metabolic pathway may underlie the observation that plasma concentrations of nicorandil appear to show a circadian rhythm, whilst saturable entry into these endogenous pools may also contribute to the small but significant plasma accumulation of the drug following repeated twice daily administration (10 to 20mg).

As a result of extensive hepatic metabolism, renal clearance of the unchanged drug is low (<1% of the original dose) and the pharmacokinetic profile of nicorandil does not appear to be significantly altered in the elderly or in patients with renal impairment (creatinine clearance <1.2 L/h). It is currently unclear whether the pharmacokinetics of nicorandil are affected to a clinically significant degree in patients with hepatic impairment.

Therapeutic Efficacy

Nicorandil has been most extensively investigated in the treatment of effort-induced angina pectoris. In comparative trials (n ⩽140 patients) lasting up to 3 months, twice daily dosage with nicorandil 10 to 20mg was as effective as standard therapy with isosorbide mononitrate, isosorbide dinitrate, propranolol, atenolol, nifedipine or diltiazem. An open-label dose titration study involving 106 patients with coronary artery disease demonstrated that twice daily regimens of nicorandil 10 to 40mg maintained an improvement in objective and subjective indicators of angina and myocardial ischaemia throughout the year-long treatment period. Few trials have investigated the efficacy of nicorandil in other types of angina, although a single short term (⩽9 days) comparative trial indicated that intravenous nicorandil (2 to 6 mg/h for 3 to 9 hours) was of equivalent efficacy to isosorbide dinitrate (2 to 6 mg/h for 3 to 9 hours) in unstable angina. In addition, nicorandil may be effective in improving the symptoms of unstable and variant angina in patients who are refractory to conventional therapy with a combination of nitrates, β- blockers and calcium antagonists. Likewise, in a 3-day noncomparative trial, nicorandil 5 to 10mg 4 times daily markedly reduced anginal attack frequency and ST segment elevation in patients with variant angina pectoris. However, as yet, no comparative studies with nitrates and/or calcium channel antagonists have been published.

Tolerability

The tolerability of nicorandil has been assessed in more than 1680 European patients. Overall, the qualitative as well as quantitative pattern of adverse events are those typically associated with vasodilator therapy; mild to moderate headache was the most frequently reported adverse event, occurring in 20 to 50% of patients treated with the recommended therapeutic dose (10 to 20mg twice daily). In comparative trials, the incidence of headache was similar to that associated with the conventional nitrate vasodilators, isosorbide mononitrate and isosorbide dinitrate. Headaches were most frequently reported during the first few days of nicorandil treatment, although they usually resolved with continued therapy. To date, headache has caused approximately 5% of patients to withdraw during European clinical trials, although the withdrawal rate may be reduced, particularly in patients prone to headache, using a starting dose (5mg twice daily) lower than the recommended therapeutic dose.

Other less common adverse events associated with nicorandil treatment include dizziness, palpitations and gastrointestinal disturbances (gastralgia, nausea and vomiting); postural hypotension leading to dizziness and syncope has been associated with high starting doses (⩾40 mg).

Heart rate was not significantly affected in long-term studies using nicorandil 10 to 80 mg/ day and there is no evidence of a proarrhythmogenic effect in patients with coronary heart disease or heart failure. Similarly, there have been no reports of unexpected drug interactions during concomitant therapy with other classes of antianginal drugs.

The tolerability profile of nicorandil appears to have been confirmed by a 6-year postmarketing surveillance study involving 14 530 Japanese patients treated with nicorandil (5 to 10mg 3 times daily), which validated that headache, gastrointestinal disturbances and dizziness were the most commonly reported adverse events.

Dosage and Administration

Nicorandil dosage should be individually titrated in order to provide acceptable relief from anginal symptoms, whilst causing minimum adverse vasodilator-related effects such as headache and postural hypotension. Clinical results indicate that an initial oral dose of 10mg twice daily, increasing to a maximum of 40mg twice daily, is effective in improving the symptoms of effort-induced angina in patients with coronary artery disease. In patients particularly prone to headache, a lower starting dose of nicorandil 5mg twice daily (for as little as 2 days) can subsequently reduce the incidence and severity of headache.

Keywords

Nicorandil Pinacidil Cardiovascular Pharmacology Isosorbide Dinitrate Variant Angina 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aizawa T, Ogasawara K, Kato K. Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S123–S129, 1987PubMedGoogle Scholar
  2. Aizawa T, Ogasawara K, Nakamura F, Hirosaka A, Sakuma T, et al. Effect of nicorandil on coronary spasm. American Journal of Cardiology 63: 75J-79J, 1989Google Scholar
  3. Araki H, Hayata N, Matsuguchi T, Nakamura M. Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate. Clinical Therapeutics 9: 174–182, 1987PubMedGoogle Scholar
  4. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Activation of myocardial ATP-gated K+ channels affords cardioprotection from stunning: a study with the K+ channel opener aprikalim. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  5. Awata N, Azuma J, Sawamura A, Harada H, Hamaguchi T, et al. Efficacy of nicorandil on exercise performance in patients with stable effort angina. Current Therapeutic Research 45: 621–632, 1989Google Scholar
  6. Belz GG, Matthews JH, Beck A, Wagner G, Schneider B. Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers. Journal of Cardiovascular Pharmacology 7: 1107–1112, 1985PubMedGoogle Scholar
  7. Berdeaux A, Drieu la Rochelle C, Richard V, Giudicelli J-F. Differential effects of nitrovasodilators, potassium channel openers and nicorandil on large and small coronary arteries in conscious dogs. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  8. Camm AJ, Maltz MB. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris. American Journal of Cardiology 63: 61J-65J, 1989Google Scholar
  9. Cavero I, Pratz J, Mondot S. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system. Zeitschrift für Kardiologie 80 (Suppl. 7): 35–41, 1991PubMedGoogle Scholar
  10. Chaitman BR. The changing role of the exercise electrocardiogram as a diagnostic and prognostic test for chronic ischaemic heart disease. Journal of American College of Cardiology 8: 1195–1210, 1986Google Scholar
  11. Chibana T, Nagamine F, Sunagawa R, Oshiro K, Nakada Y, et al. Comparison of the acute hemodynamic and coronary vasodilating effects between nicorandil and glyceryl trinitrate. Arzneimittel Forschung 41: 591–594, 1991PubMedGoogle Scholar
  12. Cohen-Solal AC, Jaeger P, Bouthier J, Juliard J-M, Dahan M, et al. Hemodynamic action of nicorandil in chronic congestive heart failure. American Journal of Cardiology 63: 44J-48J, 1989Google Scholar
  13. Coltart DJ, Signy M. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease. American Journal of Cardiology 63: 34J–39J, 1989PubMedGoogle Scholar
  14. Cook NS. The pharmacology of potassium channels and their therapeutic potential. Trends in Pharmacological Sciences 9: 21–28, 1988PubMedGoogle Scholar
  15. Di Somma S, Liquori V, Verdecchia P, Porcellati P, Bertocchi F, et al. A double-blind comparison of nicorandil and metoprolol in patients with effort stable angina. Abstract. European Heart Journal 11 (Suppl.): 8.0, 1990Google Scholar
  16. Eltze M. Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery. European Journal of Pharmacology 165: 231–239, 1989PubMedGoogle Scholar
  17. Endo T, Nejima J, Kiuchi K, Fujita S, Kikuchi K, et al. Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs. Journal of Cardiovascular Pharmacology 12: 587–592, 1988PubMedGoogle Scholar
  18. Epstein SE, Talbot TL. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris. American Journal of Cardiology 48: 797–803, 1981PubMedGoogle Scholar
  19. Escande D. The pharmacology of ATP-sensitive potassium channels in the heart. Pflügers Archives 414 (Suppl. 1): S93–S98, 1989Google Scholar
  20. Escande D, Cavero I. K+ channel openers: moving towards cardioprotection via strengthening of a natural mechanism. Trends in Pharmacological Sciences 13: 269–272, 1992PubMedGoogle Scholar
  21. Feldman RL. A review of medical therapy for coronary artery spasm. Circulation 75 (Suppl. V): V96–102, 1987PubMedGoogle Scholar
  22. Fenici RR, Melillo G. Effects of nicorandil on human cardiac electrophysiological parameters. Abstract. Cardiovascular Drugs and Therapy 5 (Suppl. 3): 367, 1991Google Scholar
  23. Flaherty JT. Nitrate tolerance: a review of the evidence. Drugs 37: 523–550, 1989PubMedGoogle Scholar
  24. Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs 39: 929–967, 1990Google Scholar
  25. Froer KL, Rackwitz R, Döring G. Antianginal and anti-ischaemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicentric double-blind randomized studies with stable coronary heart disease patients. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  26. Frydman A. Pharmacokinetic profile of nicorandil in man: an overview. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  27. Frydman AM, Chapelle P, Diekmann H, Bruno R, Thebault JJ, et al. Pharmacokinetics of nicorandil. American Journal of Cardiology 63: 25J-33J, 1989Google Scholar
  28. Fukami K, Haze K, Sumiyoshi T, Saito M, Hiramori K. Beneficial effects of intravenous nicorandil in refractory unstable angina. Abstract. European Heart Journal 9 (Suppl. 1): 64, 1988Google Scholar
  29. Furukawa K, Itoh T, Kajiwara M, Kitamura K, Suzuki H, et al. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries. Journal of Pharmacology and Experimental Therapeutics 218: 248–259, 1981PubMedGoogle Scholar
  30. Fuster V, Chesebro J. Mechanisms of unstable angina pectoris. New England Journal of Medicine 315: 1023–1025, 1986PubMedGoogle Scholar
  31. Galié N, Varani E, Maiello L, Boriani G, Boschi S, et al. Usefulness of nicorandil in congestive heart failure. American Journal of Cardiology 65: 343–348, 1990PubMedGoogle Scholar
  32. Gomita Y, Eto K, Furuno K, Mimaki Y, Araki Y. Influences of exposure to cigarette smoke on concentration of nicorandil in plasma of rats. Journal of Pharmaceutical Sciences 81: 228–231, 1992PubMedGoogle Scholar
  33. Gross GJ, Farber NE, Warltier DC, Pieper GM. Cardioprotective effect of nicorandil. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  34. Gross GJ, Pieper G, Farber NE, Warltier D, Hardman H. Effects of nicorandil on coronary circulation and myocardial ischemia. American Journal of Cardiology 63: 11J-17J, 1989Google Scholar
  35. Grover GJ, McCullough JR, Henry DE, Conder ML, Sleph PG. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. Journal of Pharmacology and Experimental Therapeutics 251: 98–104, 1989PubMedGoogle Scholar
  36. Grover GJ, Sleph PG, Parham CS. Nicorandil improves postischemic contractile function independently of direct myocardial effects. Journal of Cardiovascular Pharmacology 15: 698–705, 1990PubMedGoogle Scholar
  37. Gruetter CA, Kadowitz PJ, Ignarro LJ. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. Canadian Journal of Physiology and Pharmacology 59: 150–156, 1981PubMedGoogle Scholar
  38. Guyton AC. The coronary circulation and ischemic heart disease. Textbook of Medical Physiology, 6th ed, pp. 320–331, WB Saunders, Philadelphia, 1981Google Scholar
  39. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. General Pharmacology 20: 1–9, 1989PubMedGoogle Scholar
  40. Hashimoto K, Kinoshita M, Ohbayashi Y. Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs. Cardiovascular Drugs and Therapy 5: 131–138, 1991PubMedGoogle Scholar
  41. Hayata N, Araki H, Nakamura M. Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study. American Heart Journal 112: 1245–1250, 1986PubMedGoogle Scholar
  42. Henry PJ, Horowitz JD, Louis WJ. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. Journal of Cardiovascular Pharmacology 15: 365–370, 1990PubMedGoogle Scholar
  43. Hiasa Y, Hamai K, Wada T, Aihara T, Bando M, et al. Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris. Tokushima Journal of Experimental Medicine 36: 65–70, 1989PubMedGoogle Scholar
  44. Hinohara Y, Yamazaki T, Kuromaru O, Homma N, Sakai K. Effects of nicorandil and verapamil, antianginal agents, on plasma digoxin concentrations in rats and dogs. Journal of Pharmacy and Pharmacology 39: 512–516, 1987PubMedGoogle Scholar
  45. Hiraoka M, Fan Z. Activation of ATP-sensitive outward K+ current by nicorandil (2-nicotinamidoethyl nitrate) in isolated ventricular myocytes. Journal of Pharmacology and Experimental Therapeutics 250: 278–285, 1989PubMedGoogle Scholar
  46. Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). Journal of Cardiovascular Pharmacology 5: 364–370, 1983PubMedGoogle Scholar
  47. Holzmann S, Kukovetz WR, Braida C, Poch G. Molecular mechanism of action of nicorandil. European Journal of Pharmacology 215: 1–7, 1992PubMedGoogle Scholar
  48. Horie M, Tei M, Suzuki H, Tominaga M, Kawai C, et al. Nicorandil reduces the basal level of cytosolic free calcium in single guinea-pig ventricular myocytes. Cell Structure and Function 16: 433–440, 1991PubMedGoogle Scholar
  49. Horii D, Ishibashi A, Iwamoto A. Bioavailability study of nicorandil before and after meals. Rinsho Yakuri 15: 489–495, 1984Google Scholar
  50. Huckstorf C, Bassenge E. Effects of long-term nicorandil application on coronary arteries in conscious dogs. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  51. Hughes LO, Rose EL, Lahiri A, Raftery EB. Comparison of nicorandil and atenolol in stable angina pectoris. American Journal of Cardiology 66: 679–682, 1990PubMedGoogle Scholar
  52. Imagawa J, Akima M, Nabata H, Taira N. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide. Journal of Cardiovascular Pharmacology 19: 108–114, 1992PubMedGoogle Scholar
  53. Ishizaki T, Chiba K, Suganuma T, Sasaki T, et al. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs. Journal of Pharmaceutical Sciences 73: 494, 1984PubMedGoogle Scholar
  54. Jungbluth GL, Della-Coletta AA, Blum RA, Ferry JJ. Comparative pharmacokinetics (PK) and bioavailability of nicorandil (NIC) in subjects with stabilized cirrhosis and matched healthy volunteers. Abstract. Clinical Pharmacology and Therapeutics 49: 181, 1991Google Scholar
  55. Kakei M, Yoshinaga M, Saito K, Tanaka H. The potassium current activated by 2-nicotinamidoethyl nitrate (nicorandil) in single ventricular cells of guinea pigs. Proceedings of the Royal Society of London 229: 331–343, 1986PubMedGoogle Scholar
  56. Kambara H, Nakamura Y, Tamaki S, Kawai C. Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S104–S108, 1987PubMedGoogle Scholar
  57. Kambara H, Sasayama S, Nakano T, Hara N, Matsuyama E, et al. Evaluation of cross-tolerance between nitroglycerin and nicorandil or isosorbide dinitrates. Abstract. Cardiovascular Drugs and Therapy 3 (Suppl. 2): 599, 1989Google Scholar
  58. Kambara H, Tamaki S, Nakamura Y, Kawai C. Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function. American Journal of Cardiology 63: 56J-60J, 1989Google Scholar
  59. Kato K, Iinuma H, Hirosawa K, Sugimoto T, Uchida Y, et al. Clinical evaluation of intravenous SG-75 in treatment of unstable angina — a multicenter double-blind comparative study with intravenous ISDN. Rinsho Iyaku 7: 2031–2054, 1991Google Scholar
  60. Kato K, Asanoi H, Wakabayashi C, Hosoda S, Shiina A, et al. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S98–S103, 1987PubMedGoogle Scholar
  61. Kempsford RD, Hawgood BJ. Assessment of the anti-arrhythmic activity of nicorandil during myocardial ischaemia and reperfusion. European Journal of Pharmacology 163: 61–68, 1989PubMedGoogle Scholar
  62. Kinoshita M, Hashimoto K, Ohbayashi Y, Inoue T, Taguchi H, et al. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism. American Journal of Cardiology 63: 71J-74J, 1989Google Scholar
  63. Kinoshita M, Nishikawa S, Sawamura M, Yamaguchi S, Mitsunami K, et al. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris. American Journal of Cardiology 58: 733–738, 1986PubMedGoogle Scholar
  64. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovascular Drugs and Therapy 4: 1075–1088, 1990PubMedGoogle Scholar
  65. Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris. Clinical Pharmacology and Therapeutics 42: 166–174, 1987PubMedGoogle Scholar
  66. Kobayashi K, Hakuta T. Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S109–S115, 1987PubMedGoogle Scholar
  67. Korb H, Hoeft A, Hunneman DH, Schraeder R, Wolpers HG, et al. Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: a comparison with isosorbide dinitrate. Naunyn-Schmiedeberg’s Archives of Pharmacology 329: 440–446, 1985PubMedGoogle Scholar
  68. Krumenacker M, Roland E. Nicorandil clinical profile. An overview of its haemodynamic properties and therapeutic efficacy. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): S93–S102, 1992PubMedGoogle Scholar
  69. Kukovetz WR, Holzmann S. Cyclic GMP in nicorandil-induced vasodilatation and tolerance development. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S25–S30, 1987PubMedGoogle Scholar
  70. Kukovetz WR, Holzmann S, Poch G. Molecular mechanism of action of nicorandil. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): In press, 1992Google Scholar
  71. Lablanche JM, Bauters C, Leroy F, Bertrand ME. Prevention of coronary spasm by nicorandil: comparison with nifedipine. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  72. Lam JYT, Chesebro JH, Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation 75: 243–248, 1987PubMedGoogle Scholar
  73. Maseri A, L’Abbate A, Baroldi G, Chierchia S, Marzilli M, et al. Coronary vasospasm as a possible cause of myocardial infarction. New England Journal of Medicine 299: 1271–1277, 1978PubMedGoogle Scholar
  74. McNeil JJ, Sloman JG. Cardiovascular diseases. Avery’s Drug Treatment 3rd edn, pp. 591–675, Adis Press, Auckland, 1987Google Scholar
  75. Meany TB, Richardson P, Camm J, Coltart J, Griffith M. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. American Journal of Cardiology 63 (Suppl.): 66–70 1989Google Scholar
  76. Meeter K, Kelder JC, Tijssen JGP, Bucx JJJ, Henneman JA, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort. A long-term double-blind randomized study. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  77. Mitrovic V, Neuss H, Kindler M. Elektrophysiologische auswirkungen einer vasodilatation durch nicorandil. Herz/Kreislauf 18: 403–408, 1986Google Scholar
  78. Minamiji K, Kurogane H, Fujino, Yoshida Y. Haemodynamic effects of intravenous nicorandil: comparison with nitroglycerin. Abstract. European Heart Journal 10 (Suppl.): 74, 1989Google Scholar
  79. Mitani A, Kinoshita K, Fukamachi K, Sakamoto M, Kurisu K, et al. Effects of glibenclamide and nicorandil on cardiac function during ischaemia and reperfusion in isolated perfused rat hearts. American Journal of Physiology 261: H1864–H1871, 1991PubMedGoogle Scholar
  80. Mizumura T, Tamura Y, Saito S, Ando T, Moriuchi M, et al. Cardioprotective effect of nicorandil during percutaneous transluminal coronary angioplasty (PTCA) as viewed from intracoronary electrocardiograms. Journal of Cardiovascular Pharmacology (Suppl.) in press, 1992Google Scholar
  81. Molinaro M, Villa G, Regazzi MB, Salvadeo A, Segagni S, et al. Pharmacokinetics of nicorandil in patients with normal and impaired renal function. European Journal of Clinical Pharmacology 42: 203–207, 1992PubMedGoogle Scholar
  82. Morimoto S, Koh E, Fukuo K, Imanaka S, Hironaka T, et al. Effect of nicorandil on the cytosolic free calcium concentration and microsomal (Ca2+ + Mg2+)-ATPase activity of vascular smooth muscle cells. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S31–S37, 1987PubMedGoogle Scholar
  83. Murakami M, Takeyama Y, Matsubara H, Hasegawa S, Nakamura N, et al. Effects of intravenous injection of nicorandil on systemic and coronary hemodynamics in patients with old myocardial infarction (OMI) — a comparative study with nifedipine and ISDN. Abstract. European Heart Journal 10 (Suppl.): 426, 1989Google Scholar
  84. Nabata H, Shiraki Y, Sakai K. Development of tolerance and a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): a comparison with nitroglycerin. Japanese Journal of Pharmacology 31: 511–519, 1981Google Scholar
  85. Nagai H, Kitagaki K, Goto S, Suda H, Koda A. Effect of three novel K+ channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma. Japanese Journal of Pharmacology 56: 13–21, 1991PubMedGoogle Scholar
  86. Nakamura Y, Akima M, Sakai K. Influence of nicorandil, an antianginal agent, on the therapeutic and toxic cardiovascular actions of ouabain in the anaesthetised dog. Clinical and Experimental Pharmacology and Physiology 11: 275–283, 1984PubMedGoogle Scholar
  87. Nakayama K, Fan Z, Marumo F, Sawanobori T, Hiraoka M. Action of nicorandil on ATP-sensitive K+ channel in guinea-pig ventricular myocytes. British Journal of Pharmacology 103: 1641–1648, 1991PubMedGoogle Scholar
  88. Noma A. ATP-regulated potassium channels in cardiac muscle. Nature 305: 147–148, 1983PubMedGoogle Scholar
  89. Ogawa N, Ono H. Different effects of various vasodilators on autoregulation of renal blood flow in anesthetized dogs. Japanese Journal of Pharmacology 41: 299–306, 1986PubMedGoogle Scholar
  90. Ohnishi M, Matsuda Y, Shiotani H, Yamabe H, Maeda K, et al. The effects of nicorandil on hemodynamics and myocardial perfusion in coronary artery disease. Abstract. Cardiovascular Drugs and Therapy 3 (Suppl. 2): 618, 1989Google Scholar
  91. Ohnishi M, Matsuda Y, Shiotani H, Yamabe H, Maeda K, et al. Effects of nicorandil on hemodynamics in congestive heart failure. Abstract. European Heart Journal 11 (Suppl.): 395, 1990Google Scholar
  92. Pieper GM, Gross GJ. Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate. Circulation 76: 916–928, 1987PubMedGoogle Scholar
  93. Pratz J, Mondot S, Montier F, Cavero I. Effects of the K+channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats. Journal of Pharmacology and Experimental Therapeutics 258: 216–222, 1991PubMedGoogle Scholar
  94. Quiroz AC, Giles TD, Roffidal L, Sander GE, Haney Y, et al. Hemodynamic responses to intravenous nicorandil in congestive heart failure (CHF). Abstract. Clinical Research 38: 4A, 1990Google Scholar
  95. Richer C, Pratz J, Mulder P, Mondot S, Giudicelli JF, et al. Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sciences 47: 1693–1705, 1990PubMedGoogle Scholar
  96. Saito S, Tamura Y, Moriuchi M, Mizumura T, Hibiya K, et al. Comparative efficacy and safety of nitroglycerin, verapamil and nicorandil during coronary angioplasty. Abstract. Journal of the American College of Cardiology 17: 377A, 1991Google Scholar
  97. Sakai K. Nicorandil: animal pharmacology. American Journal of Cardiology 63: 2J-10J, 1989Google Scholar
  98. Sakai K, Akima M, Hinohara Y, Obatake N. Hypotensive effect and biotransformation of nicorandil, a new antianginal agent, administered to rats by different routes: comparison with nitroglycerin and isosorbide dinitrate. Journal of Pharmacy and Pharmacology 36: 175–181, 1984PubMedGoogle Scholar
  99. Sakai K, Kuromaru O. Nitrate tolerance: comparison of nicorandil, isosorbide dinitrate and nitroglycerin in anaesthetised dogs. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S17–S24, 1987PubMedGoogle Scholar
  100. Sakai K, Ohba Y, Akima M, Kamiyama H, Hinohara Y, et al. Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75). Japanese Journal of Pharmacology 30: 881–890, 1980PubMedGoogle Scholar
  101. Satoh K, Yamada H, Taira N. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries. Naunyn-Schmiedeberg’s Archives of Pharmacology 343: 76–82, 1991PubMedGoogle Scholar
  102. Schmid-Antomarchi H, De Weille J, Fosset M, Lazdunski M. The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+channel in insulin-secreting cells. Journal of Biological Chemistry 262: 15840, 1987PubMedGoogle Scholar
  103. Silke B, Verma SP, Ali MS, Goldhammer E, Taylor SH. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris. American Journal of Cardiology 63: 49J–55J, 1989PubMedGoogle Scholar
  104. Starling MR, Moody M, Crawford MH, Levi B, O’Rourke RA. Repeat treadmill exercise testing: variability of results in patients with angina pectoris. American Heart Journal 107: 298, 1984PubMedGoogle Scholar
  105. Suryapranata H, MacLeod D. Nicorandil and cardiovascular performance in patients with coronary artery disease. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  106. Suryapranata H, Serruys PW, De Feyter PJ, Verdouw PD, Hugenholtz PG. Coronary vasodilatory action after a single dose of nicorandil. American Journal of Cardiology 61: 292–297, 1988PubMedGoogle Scholar
  107. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): S1–S9, 1987PubMedGoogle Scholar
  108. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. American Journal of Cardiology 63: 18J-24J, 1989Google Scholar
  109. Taira N. [Nicorandil] Coronary vasodilator effect: comparison to nitrates and calcium-channel blockers. Abstract. Nicorandil: the first potassium channel activator in ischaemic heart disease, Taormina, Sicily, May 8–12, 1991Google Scholar
  110. Taira N, Satoh K, Yanagisawa T, Imai Y, Hiwatari M. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75). Clinical and Experimental Pharmacology and Physiology 6: 301–316, 1979PubMedGoogle Scholar
  111. Takano M, Noma A. Selective modulation of the ATP-sensitive K+ channel by nicorandil in guinea-pig cardiac cell membrane. Naunyn-Schmiedeberg’s Archives of Pharmacology 342: 592–597, 1990PubMedGoogle Scholar
  112. Tamura Y, Saito S, Honye J, Hibiya K, Ando T, et al. Cardioprotective effect of nicorandil during percutaneous transluminal coronary angioplasty. Abstract. European Heart Journal 11: 52, 1990Google Scholar
  113. Thormann J, Schlepper M, Kramer W, Gottwik M, Kindler M. Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects, in patients with coronary artery disease: improved left ventricular function and regional wall motion and abolition of pacing-induced angina. Journal of Cardiovascular Pharmacology 5: 371–377, 1983PubMedGoogle Scholar
  114. Tsuchioka Y, Yamagata T, Amioka H, Hashimoto M, Okamoto M, et al. Clinical electrophysiological effects of nicorandil on the conduction system in humans. Kokyu to Junkan 38: 683–686, 1990PubMedGoogle Scholar
  115. Tsutamoto T, Kanamori T, Mitsunami K, Kinoshita M. Nicorandil does not develop tolerance in patients with congestive heart failure. Abstract. Circulation 80 (Suppl. 2): 215, 1989Google Scholar
  116. Tsutamoto T, Kinoshita M, Motohara S, Uehata H, Hi-rose K, et al. Nicorandil does not develop tolerance in patients with congestive heart failure. Symposium: Second Nicorandil Research Society, 1992Google Scholar
  117. Tsutamoto T, Miyauchi N, Kanamori T, Kinoshita M. Mechanism of nicorandil intolerance in patients with heart failure. Abstract. Circulation 84 (Suppl. 2): 58, 1991Google Scholar
  118. Ulvenstam G, Diderholm E, Frithz G, Gudbrandsson T, Hedbäck B, et al. Antianginal and anti-ischaemic efficacy of nicorandil compared to nifedipine in patients with angina pectoris and coronary heart disease: a double-blind randomized multi-center study. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  119. Wagner G. Selected issues from an overview on nicorandil: tolerance, duration of action and long-term efficacy. Journal of Cardiovascular Pharmacology 20 (Suppl. 3): in press, 1992Google Scholar
  120. Yamakado T, Murayama S, Ueda K, Nakano T. Effects of nicorandil, a new antianginal K+ channel opener, on left ventricular function in coronary artery disease: comparison with nitroglycerin and nifedipine. Abstract. Journal of the American College of Cardiology 17: 378A, 1991Google Scholar
  121. Yanagisawa T, Teshigawara T, Taira N. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil. British Journal of Pharmacology 101: 157–165, 1990PubMedGoogle Scholar
  122. Yokota M, Horisawa T, Iwase M, Miyahara T, Yoshida Y, et al. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction. Journal of Cardiovascular Pharmacology 10 (Suppl. 8): SI 16–S122, 1987Google Scholar
  123. Yokota M, Shibata S. Nicorandil in the treatment of angina pectoris. Internal Medicine for the Specialist 11: 97–104, 1990Google Scholar
  124. Yoneyama F, Satoh K, Taira N. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism. Cardiovascular Drugs and Therapy 4: 1119–1126,1990PubMedGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • James E. Frampton
    • 1
  • Micaela M. Buckley
    • 1
  • Andrew Fitton
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations